Horizon Therapeutics’ Tepezza, which treats a rare autoimmune disease that affects the eye, has cleared a Phase IV trial designed to illustrate the drug’s use in a specific patient population with less severe disease. The biotech — which is set to become part of Amgen once its $28.3 billion deal…
...Horizon touts PhIV win for Tepezza; FDA sets adcomm dates for Sarepta, Pfizer, Eisai apps
Horizon Therapeutics’ Tepezza, which treats a rare autoimmune disease that affects the eye, has cleared a Phase IV trial designed to illustrate the drug’s use in a specific patient population with less severe disease. The biotech — which is set to become part of Amgen once its $28.3 billion deal…
...